Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children

Kew, Kayleigh M; Karner, Charlotta; Mindus, Stéphanie; Ferrara, Giovanni

doi:10.1002/14651858.cd009019.pub2

Cited by 85 publications

(77 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adding LABA to the same dose of ICS provides additional improvements in symptoms and lung function with a reduced risk of exacerbations 166 (Evidence A). In at-risk patients, the ICS/formoterol maintenance and reliever regimen significantly reduces exacerbations and provides similar levels of asthma control at relatively low doses of ICS, compared with a fixed dose of ICS/LABA as maintenance treatment or a higher dose of ICS, both with asneeded SABA [167][168][169][170][171] (Evidence A).…”

Section: Preferred Option (Adults/adolescents): Combination Low Dose mentioning

confidence: 99%

“…The combination of rapid-onset LABA (formoterol) and low dose ICS (budesonide or beclometasone) in a single inhaler as both the controller and the reliever medication is effective in improving asthma control, 140 and in at-risk patients, reduces exacerbations requiring OCS, and hospitalizations [167][168][169][170] (Evidence A). The combination ICS/formoterol inhaler may be taken up to a maximum total formoterol dose of 72 mcg in a day (Evidence A).…”

Section: Combination Low Dose Ics (Budesonide or Beclometasone) With mentioning

confidence: 99%

See 1 more Smart Citation

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Kumbhare

Strange

2018

Southern Medical Journal

View full text Add to dashboard Cite

Section: Preferred Option (Adults/adolescents): Combination Low Dose mentioning

confidence: 99%

Section: Combination Low Dose Ics (Budesonide or Beclometasone) With mentioning

confidence: 99%

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Kumbhare

Strange

2018

Southern Medical Journal

View full text Add to dashboard Cite

“…19,36,37,38,39 Por ello, en adolescentes o adultos con asma y tratamiento de Paso 3, 4 o 5 de mantenimiento con CEI (BUD o beclometasona) + formoterol, sugerimos la estrategia SMART usando el mismo CEI + formoterol de mantenimiento y rescate el momento que se pierde el control (exacerbaciones leves). La anterior no es una opción de manejo para crisis.…”

Section: Paso 3 En ≥ 12 Años: Terapia Combinada Con Corticosteroide Aunclassified

“…Camargo-Angeles, 35 Rogelio García-Torrentera, 20 Saraí Toral-Freyre, 20 Gabriel Montes-Narváez, 25 Héctor Solorio-Gómez, 36 Juan Rosas-Peña, 37 Sergio Jesús Romero-Tapia, 38 Adela Reyes-Herrera, 39 Francisco Cuevas-Schacht, 40 Joaquín Esquer-Flores, 41 José Antonio Sacre-Hazouri, …”

unclassified

Guía Mexicana del Asma: GUIMA 2017

Larenas-Linnemann¹,

Salas-Hernández²,

Vázquez-García³

et al. 2017

RAM

View full text Add to dashboard Cite

Este artículo debe citarse como: Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, et al. Guía Mexicana del Asma 2017. Rev Alerg Mex. 2017;64 Supl 1:s11-s128. AbstractBackground: The need for a national guideline, with a broad basis among specialists and primary care physicians was felt in Mexico, to try unifying asthma management. As several high-quality asthma guidelines exist worldwide, it was decided to select the best three for transculturation. Methods: Following the internationally recommended methodology for guideline transculturation, ADAPTE, a literature search for asthma guidelines, published 1-1-2007 through 31-12-2015 was conducted. AGREE-II evaluations yielded 3/40 most suitable for transculturation. Their compound evidence was fused with local reality, patient preference, cost and safety considerations to draft the guideline document. Subsequently, this was adjusted by physicians from 12 national medical societies in several rounds of a Delphi process and 3 face-to-face meetings to reach the final version. Results: Evidence was fused from British Thoracic Society Asthma Guideline 2014, Global Initiative on Asthma 2015, and Guía Española del Manejo del Asma 2015 (2016 updates included). After 3 Delphi-rounds we developed an evidence-based document taking into account patient characteristics, including age, treatment costs and safety and best locally available medication. Conclusion: In cooperation pulmonologists, allergists, ENT physicians, paediatricians and GPs were able to develop an evidence-based document for the prevention, diagnosis and treatment of asthma and its exacerbations in Mexico.Keywords: Clinical practice guideline; Asthma; Asthmatic exacerbation; Bronchodilator; Inhaled corticosteroid; Spirometry; Immunotherapy. IntroducciónLa presentación de este documento muestra la importancia del asma en México por su alta prevalencia, pero también por su subdiagnóstico y tratamiento deficiente, que propician un mal control de los pacientes con asma, crisis más frecuentes y sintomatología activa. En consecuencia, el asma tiene un impacto socioeconómico considerable para el paciente y la sociedad en su conjunto, al igual que afecta la calidad de vida del paciente y su familia. En México, el paciente con asma puede recibir atención médica en los ámbitos pú-blico o privado, en los diferentes niveles de salud y por múltiples especialidades. Todas estas particularidades de la situación nacional indican la necesidad de un documento guía actualizado, con base amplia en múltiples gremios médicos, tanto de primer nivel de atención como de especialidad.El objetivo de la GUIMA 2017 es facilitar la reducción de la morbimortalidad por asma en México, no solo al mejorar el conocimiento acerca de esta patología, sino también al ayudar a la parte administrativa del Sector Salud a gestionar la selección y adquisición más precisa de los medicamentos necesarios para su tratamiento a nivel de la salud pública. Para tal fin se ofrecen lineamientos par...

show abstract

“…2014 yılında yapılan Cochrane değerlendirmesinde de kombinasyon tedavilerinin güvenli olduğu bildirilmektedir (138). 2013 Cochrane değerlendirmesine budesonid formoterol fiks doz tek inhaler kullanımının, diğer separe veya fiks doz kombinasyonlara göre oral steroid gerektiren ataklar ve atak nedenli hospitalizasyon oranlarında daha iyi bir azalma sağladığı gözlenmiştir (139).…”

Section: Etkin Tedaviler Verilmesiunclassified